Q BioMed Inc (QBIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Q BioMed Inc (QBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9378
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Q BioMed Inc (Q BioMed), formerly ISMO Tech Solutions Inc, is a biomedical acceleration and development company. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It develops Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for pediatric developmental nonverbal disorder; and UTTROSIDE-B Chemotherapeutic, UTTROSIDE-B chemotherapeutic, a natural compound for the treatment for variety of liver cancer cell types. The company has partnership with Sphaera Pharma to develop an analog of QBM-001 for pediatric developmental nonverbal disorder. Q BioMed is headquartered in New York, the US.

Q BioMed Inc (QBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Q BioMed Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Q BioMed to Acquire Assets of Mannin Research 11
Partnerships 12
Q BioMed Enters into Agreement with Sphaera Pharma 12
Q BioMed Enters into Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 13
Licensing Agreements 14
Q BioMed to Expand Option Agreement with Washington University 14
Q BioMed Enters into Licensing Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 15
Q Biomed Enters into Licensing Agreement with Asdera 16
Q BioMed Amends its Licensing Agreement with Bio-Nucleonics 17
Q BioMed Enters into Option Agreement to Acquire Platform Technology Assets of Mannin Research 18
Equity Offering 19
Q BioMed Raises USD5.5 Million in Public Offering of Shares 19
Q BioMed Raises USD3 Million in Private Placement of Units 20
Q BioMed Plans to Raise Funds through Public Offering of Shares 21
Q BioMed Withdraws Public Offering of Shares for USD9.59 million 22
Q BioMed Raises Funds in Private Placement of Units 23
Q BioMed Raises USD0.1 Million in Private Placement of Units 24
Q BioMed Raises Funds in Private Placement of Units 25
Q BioMed Raises Funds in Private Placement of Units 26
Debt Offering 27
Q BioMed Raises USD1.5 Million in Final Tranche of Private Placement of 5% Debentures Due 2017 27
Q BioMed Raises USD1 Million in Second Tranche of Private Placement of 5% Debentures Due 2017 28
Q BioMed Raises USD1.5 Million in First Tranche Private Placement of 5% Debentures Due 2017 29
Q BioMed Inc – Key Competitors 30
Q BioMed Inc – Key Employees 31
Q BioMed Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Corporate Communications 33
Sep 17, 2018: Q Biomed names Dr. Rajendra Apte to advisory board 33
Feb 13, 2018: Q BioMed Adds Dr. Rick Panicucci to Board of Directors 34
Product News 35
Dec 21, 2017: Q BioMed Provides Year End Update 35
Other Significant Developments 37
Jun 06, 2018: Q BioMed Provides Important Update on Mannin Research Tie2 Technology Platform Development 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Q BioMed Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Q BioMed to Acquire Assets of Mannin Research 11
Q BioMed Enters into Agreement with Sphaera Pharma 12
Q BioMed Enters into Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 13
Q BioMed to Expand Option Agreement with Washington University 14
Q BioMed Enters into Licensing Agreement with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology 15
Q Biomed Enters into Licensing Agreement with Asdera 16
Q BioMed Amends its Licensing Agreement with Bio-Nucleonics 17
Q BioMed Enters into Option Agreement to Acquire Platform Technology Assets of Mannin Research 18
Q BioMed Raises USD5.5 Million in Public Offering of Shares 19
Q BioMed Raises USD3 Million in Private Placement of Units 20
Q BioMed Plans to Raise Funds through Public Offering of Shares 21
Q BioMed Withdraws Public Offering of Shares for USD9.59 million 22
Q BioMed Raises Funds in Private Placement of Units 23
Q BioMed Raises USD0.1 Million in Private Placement of Units 24
Q BioMed Raises Funds in Private Placement of Units 25
Q BioMed Raises Funds in Private Placement of Units 26
Q BioMed Raises USD1.5 Million in Final Tranche of Private Placement of 5% Debentures Due 2017 27
Q BioMed Raises USD1 Million in Second Tranche of Private Placement of 5% Debentures Due 2017 28
Q BioMed Raises USD1.5 Million in First Tranche Private Placement of 5% Debentures Due 2017 29
Q BioMed Inc, Key Competitors 30
Q BioMed Inc, Key Employees 31

List of Figures
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Q BioMed Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Q BioMed Inc (QBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Shenzhen Moso Power Supply Technology Co Ltd (002660):電力:M&Aディール及び事業提携情報
    Summary Shenzhen Moso Power Supply Technology Co Ltd (Moso Power) is a manufacturer of electronics and electrical appliances. The company designs and distributes consumer electronics and solar photovoltaic products. Its products include LED driver, outdoor lighting, industrial lighting, landscape li …
  • 3I Group Plc:企業の戦略・SWOT・財務分析
    3I Group Plc - Strategy, SWOT and Corporate Finance Report Summary 3I Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • CureMeta LLC-製薬・医療分野:企業M&A・提携分析
    Summary CureMeta LLC (CureMeta) is a biotechnology company that concentrates on the development of immunology therapeutics for cancers. The company advances novel antibody drug conjugates targeting pluripotent stem cells. Its pipeline product comprises Bstrongximab-ADC. CureMeta develops the antibod …
  • ERG Renew SpA:電力:M&Aディール及び事業提携情報
    Summary ERG Renew S.p.A. (ERG Renew), formerly Entad S.p.A., a subsidiary of ERG S.p.A, is a power company that generates electricity from renewable sources. The company generates electricity mainly through wind. ERG Renew and its subsidiaries operate in Italy, France, Bulgaria/Romania, Germany, and …
  • Bioasis Technologies Inc (BTI):医療機器:M&Aディール及び事業提携情報
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Purdue Pharma L.P.:企業の戦略・SWOT・財務情報
    Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report Summary Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Hamon Research-Cottrell Inc:企業の戦略的SWOT分析
    Hamon Research-Cottrell Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Buckeye Partners LP (BPL):企業の財務・戦略的SWOT分析
    Buckeye Partners LP (BPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Valeura Energy Inc (VLE):石油・ガス:M&Aディール及び事業提携情報
    Summary Valeura Energy Inc (Valeura) is an upstream oil and gas company that explores for, develops and produces oil and natural gas. It operates mainly in the Thrace Basin in the northwest of Turkey pursuing conventional shallow natural gas, unconventional tight gas and a basin-centered gas accumul …
  • AGCO Corporation (AGCO):企業の財務・戦略的SWOT分析
    AGCO Corporation (AGCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Shangri-La Hotels (Malaysia) Berhad:企業の戦略・SWOT・財務情報
    Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Bachmann electronic GmbH:企業の戦略的SWOT分析
    Bachmann electronic GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Zimmer Biomet Holdings Inc (ZBH):医療機器:M&Aディール及び事業提携情報
    Summary Zimmer Biomet Holdings Inc (Zimmer Biomet) is a medical device company with focus on musculoskeletal healthcare. The company designs, manufactures, and markets orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, craniomaxillofacial and tho …
  • ArcelorMittal:企業のM&A・事業提携・投資動向
    ArcelorMittal - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ArcelorMittal Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Bechtel Corp:企業の戦略的SWOT分析
    Bechtel Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Kinnov Therapeutics SAS-製薬・医療分野:企業M&A・提携分析
    Summary Kinnov Therapeutics SAS (Kinnov) is a research and development company that discovers and develops therapies against addiction. The company’s pipeline product include KT-110, a pharmaceutical composition used as a therapy for addiction diseases. Its antagonist of alpha1-adrenergic receptors …
  • Office Depot, Inc.:戦略・SWOT・企業財務分析
    Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MDNA Life Sciences Inc-医療機器分野:企業M&A・提携分析
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test (PCMT) based on the science of mitochondrial DNA (mtDNA) is a tissue-based prostate cancer diagnostics for prostate and o …
  • Aon plc:企業のM&A・事業提携・投資動向
    Aon plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aon plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Serinus Energy Plc (SEN):石油・ガス:M&Aディール及び事業提携情報
    Summary Serinus Energy Plc (Serinus), formerly Serinus Energy Inc is an oil and gas company that explores and produces oil and natural gas products. The company explores, acquires and develops crude oil and natural gas reserves. It holds 100% interest in Satu Mare Concession located in the Eastern P …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆